Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. van Dyck CH, et al. Among authors: vellas b. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.
Angioni D, Delrieu J, Hansson O, Fillit H, Aisen P, Cummings J, Sims JR, Braunstein JB, Sabbagh M, Bittner T, Pontecorvo M, Bozeat S, Dage JL, Largent E, Mattke S, Correa O, Gutierrez Robledo LM, Baldivieso V, Willis DR, Atri A, Bateman RJ, Ousset PJ, Vellas B, Weiner M. Angioni D, et al. Among authors: vellas b. J Prev Alzheimers Dis. 2022;9(4):569-579. doi: 10.14283/jpad.2022.85. J Prev Alzheimers Dis. 2022. PMID: 36281661 Free PMC article.
Editorial: We Have Turned the Corner.
Aisen PS, Vellas B. Aisen PS, et al. Among authors: vellas b. J Prev Alzheimers Dis. 2022;9(S1):S5-S6. doi: 10.14283/jpad.2022.95. J Prev Alzheimers Dis. 2022. PMID: 36471006 No abstract available.
Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape.
Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O'Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Schindler SE. Hampel H, et al. Among authors: vellas b. Neuron. 2023 Sep 20;111(18):2781-2799. doi: 10.1016/j.neuron.2023.05.017. Epub 2023 Jun 8. Neuron. 2023. PMID: 37295421 Free PMC article. Review.
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force.
Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, Agus S, Sims JR, Bittner T, Carrillo MC, Fillit H, Masters CL, Salloway S, Aisen P, Weiner M, Vellas B, Gauthier S. Angioni D, et al. Among authors: vellas b. J Prev Alzheimers Dis. 2023;10(3):418-425. doi: 10.14283/jpad.2023.68. J Prev Alzheimers Dis. 2023. PMID: 37357282
Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
Caprioglio C, Ribaldi F, Visser LNC, Minguillon C, Collij LE, Grau-Rivera O, Zeyen P, Molinuevo JL, Gispert JD, Garibotto V, Moro C, Walker Z, Edison P, Demonet JF, Barkhof F, Scheltens P, Alves IL, Gismondi R, Farrar G, Stephens AW, Jessen F, Frisoni GB, Altomare D; AMYPAD consortium. Caprioglio C, et al. JAMA Netw Open. 2023 Jan 3;6(1):e2250921. doi: 10.1001/jamanetworkopen.2022.50921. JAMA Netw Open. 2023. PMID: 36637820 Free PMC article.
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial.
Altomare D, Barkhof F, Caprioglio C, Collij LE, Scheltens P, Lopes Alves I, Bouwman F, Berkhof J, van Maurik IS, Garibotto V, Moro C, Delrieu J, Payoux P, Saint-Aubert L, Hitzel A, Molinuevo JL, Grau-Rivera O, Gispert JD, Drzezga A, Jessen F, Zeyen P, Nordberg A, Savitcheva I, Jelic V, Walker Z, Edison P, Demonet JF, Gismondi R, Farrar G, Stephens AW, Frisoni GB; Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Consortium. Altomare D, et al. JAMA Neurol. 2023 Jun 1;80(6):548-557. doi: 10.1001/jamaneurol.2023.0997. JAMA Neurol. 2023. PMID: 37155177 Free PMC article. Clinical Trial.
Effect of a 1-Year Nutritional Blend Supplementation on Plasma p-tau181 and GFAP Levels among Community-Dwelling Older Adults: A Secondary Analysis of the Nolan Trial.
Giudici KV, de Souto Barreto P, Guyonnet S, Cantet C, Zetterberg H, Boschat C, Hudry J, Andrieu S, Schmitt JAJ, Vellas B, Blennow K; NOLAN/DSA group. Giudici KV, et al. Among authors: vellas b. JAR Life. 2023 Jun 12;12:25-34. doi: 10.14283/jarlife.2023.7. eCollection 2023. JAR Life. 2023. PMID: 37351539 Free PMC article.
Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study.
Bader I, Bader I, Lopes Alves I, Vállez García D, Vellas B, Dubois B, Boada M, Marquié M, Altomare D, Scheltens P, Vandenberghe R, Hanseeuw B, Schöll M, Frisoni GB, Jessen F, Nordberg A, Kivipelto M, Ritchie CW, Grau-Rivera O, Molinuevo JL, Ford L, Stephens A, Gismondi R, Gispert JD, Farrar G, Barkhof F, Visser PJ, Collij LE; AMYPAD consortium. Bader I, et al. Among authors: vellas b. Alzheimers Res Ther. 2023 Nov 2;15(1):189. doi: 10.1186/s13195-023-01332-4. Alzheimers Res Ther. 2023. PMID: 37919783 Free PMC article.
1,136 results